IP Library Granted Patent US 11,426,398
Granted Patent B2
US 11,426,398 · App. 15/735,066 · Granted Aug 30, 2022

Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Inventors: Eric A. Marcotulli (New York, NY); Daniel A. Alminana (New York, NY); Paul M. Bowen (Newton, MA)
Assignee: Elysium Health, Inc.
A61K31/455A61K8/368A61K8/675A61K9/0053A61K9/4866A61K31/09A61K31/706A61P17/00A61Q19/004A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,398
App. No.
15/735,066
Granted
Aug 30, 2022
Kind
B2
Abstract

Compositions containing a combination of nicotinamide riboside and pterostilbene for treating skin disorders, and methods of treating skin disorders using these compositions and their equivalents are described. The skin disorders that are treated using these compositions or methods include sun exposure-related skin disorders, inflammatory skin disorders, autoimmune disease-related skin disorders and cancer-related skin disorders. In one embodiment, the compositions containing a combination of nicotinamide riboside and pterostilbene are prepared as oral formulations.

Claims (3)

1. A method of treating a skin disorder caused by exposure to sun in a patient in need thereof comprising orally administering a combination of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene, wherein the therapeutically effective amount of nicotinamide riboside is about 250 mg per day, and the therapeutically effective amount of pterostilbene is about 50 mg per day, and wherein the therapeutically effective amount of nicotinamide riboside and the therapeutically effective amount of pterostilbene are administered to the subject daily.

2. The method of claim 1 , wherein the skin disorder caused by exposure to the sun is selected from the group consisting of actinic keratoses, lentigines or age spots, seborrheic keratoses, sun burn, photosensitivity, moles, polymorphous light eruption, solar elastosis or wrinkles, skin cancer, and freckles.

3. The method of claim 1 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of microcrystalline cellulose, hypromellose, vegetable magnesium stearate, olive oil, gelatin, glycerin, purified water, beeswax yellow, sunflower lecithin, silicon dioxide, titanium dioxide, FD & C Blue 1 and FD & C Red 4.

Assignments (2)
SECURITY INTEREST Recorded May 28, 2021
From: ELYSIUM HEALTH, INC.
To: VENTURE LENDING & LEASING IX, INC.
Reel/Frame 056388/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2019
From: MARCOTULLI, ERIC A.; ALMINANA, DANIEL A.; BOWEN, PAUL M.
To: ELYSIUM HEALTH, INC.
Reel/Frame 050946/0555 →
Continuity (2)
Provisional Application 62173733 · Jun 10, 2015
Related Publication 20180353497A1 · Dec 13, 2018